Chartwell Investment Partners, LLC Chemo Centryx, Inc. Transaction History

Chartwell Investment Partners, LLC

$2.91 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Jul 19, 2021	SELL	$9.59 - $50.88 $119,203 - $632,438	-12,430 Closed	0 $0
Q1 2021 May 03, 2021	SELL	$49.53 - $68.4 $33,036 - $45,622	-667 Reduced 5.09%	12,430 $637,000
Q4 2020 Feb 09, 2021	SELL	$47.25 - $65.16 $753,826 - $1.04 Million	-15,954 Reduced 54.92%	13,097 $811,000
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $217,474 - $289,449	4,692 Added 19.26%	29,051 $1.59 Million
Q2 2020 Jul 29, 2020	SELL	$38.58 - $65.07 $343,246 - $578,927	-8,897 Reduced 26.75%	24,359 $1.4 Million
Q1 2020 Apr 30, 2020	BUY	$32.73 - $50.78 $403,888 - $626,625	12,340 Added 59.0%	33,256 $1.34 Million
Q4 2019 Jan 29, 2020	BUY	$6.81 - $39.55 $142,437 - $827,227	20,916 New	20,916 $827,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chartwell Investment Partners, LLC with notifications on news.